![Kanya Rajangam](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kanya Rajangam
Plus aucun poste en cours
Fortune : 31 416 $ au 31/05/2026
Profil
Kanya Rajangam is Independent Director at Turnstone Biologics, Inc. since 2011.
Dr. Rajangam is President & Chief Medical Officer at Senti Biosciences Holdings, Inc. starting in 2026.
Dr. Rajangam is President, Chief Medical Officer, Head-R&D at Senti Biosciences, Inc. since 2024.
Former roles include Executive Director at Nektar Therapeutics in 2015; Senior Medical Director at Onyx Pharmaceuticals, Inc. from 2011 to 2015; Associate Medical Director at Exelixis, Inc. from 2008 to 2011; Independent Director at Turnstone Biologics Corp.
from 2021 to 2025; Chief Medical Officer at Cleave Therapeutics, Inc. from 2016 to 2017; Chief Medical Officer & Senior Vice President at Atara Biotherapeutics, Inc. from 2017 to 2018; Chief Medical Officer at Nkarta, Inc. from 2019 to 2022.
Education includes a doctorate from Northwestern University conferred in 2006 and a doctorate from St. John's Medical College conferred in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,11 % | 27/03/2026 | 33 000 ( 0,11 % ) | 31 416 $ | 31/05/2026 |
Postes actifs de Kanya Rajangam
| Sociétés | Poste | Début |
|---|---|---|
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Develops bio-therapeutics for the treatment of cancer | Directeur/Membre du Conseil | 01/11/2011 |
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | President | 14/05/2024 |
Anciens postes connus de Kanya Rajangam
| Sociétés | Poste | Fin |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Directeur/Membre du Conseil | 11/08/2025 |
| NKARTA, INC. | Directeur Technique/Scientifique/R&D | 05/06/2022 |
| ATARA BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2018 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicine for oncology and neurodegeneration treatment | Directeur Technique/Scientifique/R&D | 01/07/2017 |
| NEKTAR THERAPEUTICS | Directeur/Membre du Conseil | 01/05/2015 |
Formation de Kanya Rajangam
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
90
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicine for oncology and neurodegeneration treatment | Health Technology |
St. John's Medical College
 St. John's Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Develops bio-therapeutics for the treatment of cancer | Health Technology |
Nkarta, Inc.
 Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
Turnstone Biologics Corp.
 Turnstone Biologics Corp. BiotechnologyHealth Technology Develops and sells medicines to treat and cure solid tumors | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
